Participants randomised to exercise training: Will have their medication reviewed by the study clinician. Those with a HbA1c ≤ 8% who are currently taking a sulphonylurea will initially have the dose reduced by 50% 72hours prior to the first exercise session. Their regimes will be continued to be down titrated starting with the sulphonylurea and then moving, where applicable, onto their current SGLT or DPP-IV or GLP-1 therapies according to glycaemic control. The latter therapies will be titrated down last given their relative low risk of hypoglycaemic events. For those participants with a HbA1c ≤ 8% who are not taking a sulphonylurea the study clinician will down titrate glucose-lowering therapy on an individual basis, taking into account the class and combination of therapies prescribed. All other medication will be maintained unless the study clinician deems alterations are necessary for a patient's best interest. Any alterations will be recorded in the CRF and statistically adjusted for in the analysis.